对于如何在有限诊疗时间内做好科普工作，中国医科大学附一医院第一临床学院感染一科主任张静 萍建议，可根据公众近期重点关注的问题，设计一些直击热点、痛点的话题，用"一烧二痛三乏力"等公 众喜闻乐见的标语，搭配科普视频、健康贴士、科普文章等多种形式的内容，提高公众对流感疾病的认 知。 "公众最常见的问题是将流感和普通感冒划等号，这一误区说明普通大众对流感病原体的认知不 足。且在流感治疗中，公众常喜欢用抗菌药物去治疗病毒性感染，这种盲目使用抗生素的行为也是常见 误区。此外，公众对是否可接种、何时应接种流感疫苗等同样存在认知误区。"北京大学第三医院教学 副院长、感染疾病中心主任沈宁认为，专业人员要运用健康科普，为其破除认知"迷雾"，帮助公众 少"踩坑"。 华中科技大学同济医学院附属同济医院感染病学教研室主任、感染科主任宁琴说："当前，年轻人 生活节奏快、工作压力大，但年轻人易盲目信赖自身体质与免疫力，认为流感防控的重点仅针对老年人 群、婴幼儿、基础病人群等群体，缺乏对流感的重视。此外，流感进展速度较快，很多人喜欢'扛一 扛'，但若在'黄金48小时'防控阶段使用适宜药物，可以大幅度改善预后情况。" 首都医科大学附属北京佑 ...

Core Points - The "2025 Influenza Prevention and Control Science Popularization Action" aims to enhance public awareness and protective capabilities against influenza as the flu season approaches [1][3] - Experts emphasize the need for a systematic and high-quality approach to health science popularization, focusing on targeted content for key populations and utilizing modern communication methods [1][2] - The current influenza situation shows an upward trend, particularly with the H3N2 subtype, necessitating vaccination for high-risk groups [1][3] Group 1 - The event held on November 15 in Beijing focused on sharing experiences and innovations in influenza prevention and control [1] - Gao Fu, an academician, called for a normalized science popularization mechanism to enhance the quality and effectiveness of health knowledge dissemination [1][2] - Li Hao from the Chinese Center for Disease Control and Prevention acknowledged the progress made under the Healthy China strategy but stressed the ongoing threats of infectious diseases [1][3] Group 2 - The "2025 Influenza Prevention and Control Science Popularization Action" was launched online on September 24, with support from various organizations [3] - Experts highlighted the importance of medical professionals in educating the public about influenza prevention to reduce misconceptions and improve early diagnosis and treatment awareness [3] - The event showcased high-quality science popularization works related to influenza prevention and included a ceremony for appointing experts [2]

（记者 曾健辉） 每经AI快讯，有投资者在投资者互动平台提问：能否介绍下海正药业的CMO业务？公司是否把这业务 当作核心业务之一？公司和哪些药业有合作？ 海正药业（600267.SH）11月14日在投资者互动平台表示，尊敬的投资者您好！公司CMO业务目前主要 由台州和富阳基地承接，具体业务受客户端制剂需求影响，存在一定的不确定性，但总体保持一个健康 稳定的发展态势。 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 本次会议是否有否决议案：无 一、会议召开和出席情况 (一)股东会召开的时间：2025年11月12日 (二)股东会召开的地点：浙江海正药业股份有限公司会议室（台州市椒江区外沙路46号） (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： ■ 注：截止本次股东会股权登记日，公司总股本为1,198,848,196股，其中公司回购专用账户的股份数量为 36,291,300股，该等回购的股份不享有表决权，故本次股东会享有表决权的股份总数为1,162,556,896 股。 (四)表决方式是否符合《公司法》及《公司章程》的规定，股东会主持情况等。 公司2025年第二次临时股东会采用现场投票和网络投票相结合的表决方式审议有关议案，本次股东会由 浙江海正药业股份有限公司董事会召集，董事长肖卫红先生主持。会议召集、召开及表决方式符合《公 司法》等有关法律法规和《公司章程》的规定。 2、公司董事会秘书沈锡飞先生出席本次会议；部分高管列席本次会议。 二、议案审议情况 ...

北京康达（杭州）律师事务所 BEIJING KANGDA（HANGZHOU）LAW FIRM 电话/Tel.:0571-85779929 传真/Fax:0571-85779955 网址/Website:www.kangdalawyers.com 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京康达（杭州）律师事务所 关于浙江海正药业股份有限公司 2025 年第二次临时股东会的 康达(杭州)股会字【2025】第 0030 号 二〇二五年十一月 杭州市上城区西子国际中心 2 号楼 1501-1503 室 邮编：310020 北京康达（杭州）律师事务所 海正药业 2025 年第二次临时股东会法律意见书 北京康达（杭州）律师事务所 关于浙江海正药业股份有限公司 2025 年第二次临时股东会的法律意见书 康达(杭州)股会字【2025】第 0030 号 致：浙江海正药业股份有限公司 北京康达（杭州）律师事务所（下称"本所"）接受浙江海正药业股份有限 公司（下称"海正药业"或"公司"）委托，指派本所律师出席公司 2025 年第 ...

证券代码：600267 证券简称：海正药业 公告编号：临2025-69号 浙江海正药业股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一)股东会召开的时间：2025 年 11 月 12 日 (二)股东会召开的地点：浙江海正药业股份有限公司会议室（台州市椒江区外沙 路 46 号） (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 552 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 493,903,134 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 42.4842 | 注：截止本次股东会股权登记日，公司总股本为 1,198,848,196 股，其中公司回购专用账户 的股份数量为 36,291,300 股，该等回购的股份不享有表决权，故本次股东会享有表决权的 ...

Core Viewpoint - Zhejiang Haizheng Pharmaceutical Co., Ltd. has approved the public transfer of 100% equity of its wholly-owned subsidiary, Zhejiang Pharmaceutical Industry Co., Ltd., to optimize its business structure and focus on core advantages in the pharmaceutical industry [1][2] Group 1 - The board of directors has confirmed that the announcement contains no false records, misleading statements, or significant omissions, and they bear legal responsibility for its authenticity, accuracy, and completeness [1] - The equity of Zhejiang Pharmaceutical Industry Co., Ltd. is assessed at 392.2339 million yuan, with a proposed public listing price of 430 million yuan [1] - The public transfer application for the equity was submitted to Taizhou Property Rights Exchange on November 10, 2025, with the listing period from November 11 to December 8, 2025 [2] Group 2 - The company has provided details for the public transfer on the websites of Zhejiang Property Rights Exchange and Taizhou Property Rights Exchange, and investors can inquire further by phone [2] - There is a potential risk of unsuccessful delisting for the public transfer of the equity, and the company will fulfill its information disclosure obligations based on the progress of this matter [2] - The designated media for information disclosure includes China Securities Journal, Shanghai Securities Journal, Securities Times, and the Shanghai Stock Exchange website [2]

Core Insights - The article emphasizes the importance of expanding domestic demand as a strategic foundation, integrating consumer welfare and investment to stimulate new supply and demand dynamics [1] Group 1: Online and Offline Integration - The "Double 11" shopping festival showcased a deep integration of online and offline retail, allowing consumers to experience products in-store while also having the option to order online for home delivery [2] - Data indicates a 30% year-on-year increase in foot traffic at JD MALL, with home goods sales surging by 191% and full-home customization sales increasing nearly sevenfold [3] Group 2: Consumption Model Evolution - The event highlighted a shift from merely purchasing goods to enjoying services, with the automotive aftermarket seeing significant growth through online ordering and in-store services [4] - The integration of industrial products into the "Double 11" promotions has also been noted, with a 40% reduction in procurement communication costs for clients [4] Group 3: Global Market Expansion - The "Double 11" event expanded its reach to 20 countries and regions, with a marketing investment of 1 billion yuan aimed at doubling overseas transactions for 100,000 merchants [5] - Cross-border services saw a 300% increase in transaction volume, with user numbers growing by over 400% [4][5] Group 4: Supply and Demand Alignment - The C2M (Customer-to-Manufacturer) model has enabled precise matching of supply and demand, leading to successful product launches such as a new thermos that set sales records [6] - In the 3C digital sector, C2M collaborations resulted in significant sales growth, with AI products seeing over 100% year-on-year increases [6] Group 5: Automotive Sector Dynamics - The automotive sector is experiencing renewed vitality through supply-demand integration, with new electric vehicles being launched that cater to consumer preferences for price, space, safety, and range [7]

Core Viewpoint - The company has decided to publicly transfer 100% equity of its wholly-owned subsidiary, Zhejiang Provincial Pharmaceutical Industry Co., Ltd., to optimize its business structure and focus on core advantages in the pharmaceutical industry, aiming to enhance overall profit margins and resource allocation efficiency [1] Summary by Relevant Sections - **Equity Transfer Announcement** - On November 11, 2025, the company announced the decision to transfer 100% equity of its subsidiary through a public listing [1] - The assessed value of the subsidiary's equity is 392.2339 million, with a proposed public listing base price of 430 million [1] - The application for the equity transfer was submitted to the Taizhou Property Rights Exchange on November 10, 2025, with the official listing period from November 11, 2025, to December 8, 2025 [1]

Group 1 - The People's Bank of China reported that as of the end of September, listed companies disclosed plans to apply for stock repurchase and increase loan limits exceeding 330 billion yuan, with financial institutions signing contracts for approximately 330 billion yuan and disbursing over 120 billion yuan [1] - The global installed capacity of power batteries reached approximately 768.3 GWh in the first nine months of 2025, a year-on-year increase of 35%, driven by the sales of new energy vehicles, which totaled about 14.24 million units, up 26% year-on-year [1] - The global revenue of communication service providers is expected to reach 5.6 trillion USD by 2030, with a compound annual growth rate (CAGR) of 6.2% starting from 2025, primarily due to technological innovation and infrastructure expansion [2] Group 2 - In Q3 2025, China's foldable smartphone shipments reached 2.63 million units, marking a year-on-year increase of 17.8%, with total shipments for the first three quarters reaching 7.62 million units, up 14.3% [2] - Multiple silicon wafer companies have reduced prices due to a supply-demand imbalance, with prices for various types of silicon wafers ranging from 1.25 to 1.65 yuan per piece [2] - Tesla is preparing to expand its Texas Gigafactory to achieve an annual production capacity of 10 million units of the Optimus humanoid robot, with mass production expected to start in 2027 [3] Group 3 - AMD has completed the acquisition of AI inference startup MK1, which will enhance AMD's capabilities in high-speed inference and enterprise-level AI software [4] - Nissan's global sales fell by 7.27% in the first half of the 2025 fiscal year, leading to a net loss of 221.92 billion yen, marking the first half-year loss in five years [7][8] - Citic Securities has been approved to publicly issue short-term corporate bonds not exceeding 50 billion yuan [11]